The CBR3 Knockout MES-OV Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the CBR3 gene in the MES-OV human ovarian clear cell carcinoma cell line. This loss-of-function model is generated by CRISPR/Cas9-mediated gene disruption, producing a heterogeneous population of cells with targeted disruption of CBR3, enabling functional studies without clonal selection.
MES-OV cells are derived from human ovarian clear cell carcinoma and serve as an established epithelial ovarian cancer model that exhibits intrinsic chemoresistance. They are widely used to investigate ovarian cancer progression, metastasis, and drug resistance, particularly reflecting the biology of the clear cell carcinoma subtype often refractory to platinum-based therapies.
CBR3 encodes carbonyl reductase 3, an NADPH-dependent short-chain dehydrogenase/reductase that detoxifies carbonyl compounds including quinones, prostaglandins, and lipid peroxidation products such as 4-hydroxynonenal. CBR3 is transcriptionally regulated by Nrf2 following oxidative stress and Keap1 signaling, and is also induced by HIF-1?? under hypoxic conditions, with modulation by STAT3 and NF-??B. It interacts with NADPH and reduces substrates like doxorubicin, thereby diminishing their cytotoxicity. CBR3 thus functions downstream of stress-responsive transcription factors to mitigate oxidative damage and drug efficacy.
In MES-OV cells, CBR3 upregulation contributes to anthracycline chemoresistance by enhancing drug metabolism. The knockout polyclonal population allows researchers to dissect CBR3??s role in drug detoxification and oxidative stress management. Comparing knockout versus wild-type cells illuminates how loss of this reductase influences sensitivity to doxorubicin and other carbonyl-containing agents, and clarifies its impact on cancer cell survival under therapeutic stress.
Key applications include chemoresistance studies, ovarian cancer drug metabolism, oxidative stress response analysis, and cancer cell survival assays. These cells are compatible with Western blotting, RT-qPCR, drug sensitivity assays (MTT with doxorubicin), carbonyl reductase activity assays, ROS measurement, annexin V apoptosis assays, and immunofluorescence. For more information, please contact Ascent Research.
